Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 338

Results For "PAT"

7299 News Found

Dr. Reddy's issues nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US
News | March 18, 2025

Dr. Reddy's issues nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US

The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m


CKD cases surge to 16.38% in Indians aged 15+
Healthcare | March 17, 2025

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care


Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals
Opinion | March 17, 2025

Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals

Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant


Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India
News | March 13, 2025

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M


Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’
News | March 13, 2025

Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’

Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure


Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
News | March 13, 2025

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD


Sigachi Industries signs MoU with INS Kalinga to promote healthy living
News | March 13, 2025

Sigachi Industries signs MoU with INS Kalinga to promote healthy living

The programme will take place on the 2nd Sunday of every month


Zydus to acquire majority stake in Amplitude Surgical, France
News | March 12, 2025

Zydus to acquire majority stake in Amplitude Surgical, France

Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies


Syngene acquires first US biologics facility for $36.5 million
News | March 11, 2025

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million


Astellas and YASKAWA to establish JV focused on cell therapy manufacturing
News | March 10, 2025

Astellas and YASKAWA to establish JV focused on cell therapy manufacturing

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients